Join us for a fundraising event on Saturday, August 5th from 1-3 PM at Kendra Scott Soutport in Chicago to raise money for esophageal cancer awareness and research efforts! 20% of all proceeds will benefit The Salgi Esophageal Cancer Research Foundation. Enjoy sips, sweets and jewels!
Kendra Scott Southport
3426 N Southport Avenue
Chicago, Illinois
Not going to be in Chicago that day, but want to participate? Not a problem! You can place a phone order starting August 2nd up until Saturday, August 5th. The phone number is 708-669-0230.
Together we can raise awareness, and get one step closer to ending esophageal cancer once and for all!
Please help us make this a great success by sharing this event on Facebook, click here, and share the image below on Instagram! Tag us in your posts @SalgiFoundation. Thank you!
The Salgi Esophageal Cancer Research Foundation hosted the 6th Annual Esophageal Cancer Walk/Run on Saturday, June 17, 2017 at Warwick City Park. The annual events aim to raise awareness and funding for esophageal cancer advocacy and research.
We would like to thank everyone who helped make Rhode Island’s 6th Annual Esophageal Cancer Walk/Run a great success! Thank you to all of the walkers, runners, sponsors, volunteers and donors! We look forward to more events in the future to further this mission in support of awareness, early detection and research funding for esophageal cancer!
Due to the success of previous fundraising events, The Salgi Foundation was able to award esophageal cancer research funding for the very first time in July 2015! This goal was achieved in less than five years since the charity first founded. This research was accepted by the American Gastroenterological Association (AGA) Institute Council and was presented as a poster presentation during Digestive Disease Week (DDW) held in Chicago, IL in May, 2017. While this was a major accomplishment, there is still so much more work that needs to be done and worthy research that needs to be funded.
Volunteers are needed for the 2018 event. Please contact us for information! SALGI.org/volunteer
Visit our Facebook page to view photos from the event. Please feel free to tag! …and remember to “like” and “share” our page! Thank youKimberli Photographyfor taking photos of the event! Visit her website: KimberliPhoto.com
Visit our YouTube channel to view the video from the event. Please remember to subscribe and share!
Thank you to Eric Simmons for taking the time to create this video! Visit his website: Grrrmedia.com
The Salgi Esophageal Cancer Research Foundation will host the 6th Annual Esophageal Cancer Walk/Run on Saturday, June 17th, at Warwick City Park in Warwick, Rhode Island at 10 AM. The event aims to raise awareness and funding for esophageal cancer advocacy and research. Sign up today! salgiwalkrun2017.eventbrite.com.
Periwinkle sponsor for the 6th Annual Esophageal Cancer Walk/Run is General Dynamics Electric Boat.
Tickets are $20 in advance or $25 the day of; children 12 and under and dogs are admitted free! T-shirts are available only for pre-paid guests who have registered by Friday, May 26th, 2017. Guests may sign up individually or as a team. To register or for more information, please visit: salgiwalkrun2017.eventbrite.com.
Those who are unable to attend the event but would still like to donate may visit: SALGI.org/donate.
Guests and supporters may create a personalized online fundraising page to help The Salgi Esophageal Cancer Research Foundation make an even bigger impact. Registration is not required to create a fundraising page. Please visit: Crowdrise.com/EsophagealCancer2017.
Sponsorship opportunities are still available for the 6th Annual Esophageal Cancer Walk/Run. Click here to learn more.
The Salgi Esophageal Cancer Research Foundation awarded its first-ever grant to esophageal cancer research in July, 2017. This research was accepted by the American Gastroenterological Association (AGA) Institute Council and an abstract was presented during Digestive Disease Week (DDW) 2017.
Since The Salgi Esophageal Cancer Research Foundation first funded research in 2015, over 20 investigators have inquired about their funding program. The charity is working diligently in hopes of funding more research within the next year.
About Esophageal Cancer: Acid reflux disease is one of the primary risk factors associated with esophageal cancer. Chronic heartburn, obesity, poor nutrition, tobacco use and excessive alcohol use are all risk factors. Esophageal cancer is among the fastest growing and deadliest cancers in the United States. With over a 600% increase in the past decades, the overall five-year survival rate is only 18.4%.
There are no standard or routine screenings to detect esophageal cancer in its earlier stages. Symptoms, such as difficulty swallowing, typically appear once the cancer has become advanced. Despite its rapid increase and poor prognosis, esophageal cancer receives very little awareness and research funding.
Please join The Salgi Esophageal Cancer Research Foundation in making this event a great success. Visit, like and share our Facebook page and invite your friends to do so as well! https://www.facebook.com/SalgiFoundation
The Salgi Esophageal Cancer Research Foundation has been invited to participate in the Pawtucket Red Sox’sPaws for a Cause event.
On Friday, July 7th at 7:05 PM, The Salgi Esophageal Cancer Research Foundation will visit the PawSox for their home-game against the Buffalo Bisons.
The Salgi Esophageal Cancer Research Foundation will be introduced on the field during the pre-game ceremonies. Our mission of raising awareness and research funding for esophageal cancer will be delivered over the stadium’s communications system for all guests to hear. We will also visit the PawSox broadcast booth for an inning during the game!
Tickets can be purchased through our unique ticket link, here.
For every ticket that we sell through this unique link, half of the money will go directly to The Salgi Esophageal Cancer Research Foundation to help fund our programs dedicated to esophageal cancer awareness, early detection and research!
Please help us make this a great night by sharing this post with everyone you know! Family, friends and co-workers. Thank you!
In July 2015, The Salgi Esophageal Cancer Research Foundation awarded esophageal cancer research funding for the very first time. This feat was accomplished in less than five years since our inception.
The research was awarded to Dr. Carlos Minacapelli and his team of researchers. The study titled “Chemoprevention studies on an in-vitro Barrett’s Epithelium Carcinogenesis model targeting CYP1 biomarker(s) by natural product Curcumin” was completed at the Crohn’s and Colitis Center of New Jersey, Division of Gastroenterology, Department of Medicine, Rutgers Robert Wood Johnson Medical School.
The American Gastroenterological Association (AGA) Institute Council accepted Dr. Minacapelli’s abstract to be presented as a poster presentation on Monday, May 8, 2017, during Digestive Disease Week (DDW) held in Chicago, IL. The abstract is entitled “Effect of Benzo[a]pyrene along with Acid and Bile is highly carcinogenic as shown in the in-vitro Barrett’s Esophagus Carcinogenesis (BEC) model.”
We are proud to have been a part of this research and will continue to prioritize funding research of esophageal cancer until a cure is found. To learn more about our esophageal cancer research, our funding program and how you can help, please visit: salgi.org/research
Effect of Benzo[A]Pyrene Along with Acid and Bile is Highly Carcinogenic as Shown in Thein-Vitro Barrett’s Esophagus Carcinogenesis (BEC) Model Minacapelli, Carlos D. et al. Gastroenterology , Volume 152 , Issue 5 , S834 – S835
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
April is Esophageal Cancer Awareness Month! This month, Bravelets has partnered with our charity to help raise awareness and funding for esophageal cancer research and advocacy.
Our President, Linda Molfesi, was able to share our mission and history with their team. Visit their blog page here to read what she had to say.
Through the end of April, 2017, you can donate 20% of your purchase to The Salgi Esophageal Cancer Research Foundation with code: SALGI20 at checkout. Visit our Bravelets Brave Page here.
To learn more about Bravelets, their mission, history and why they decided to partner with The Salgi Esophageal Cancer Research Foundation, keep reading below!
What is Bravelets’ mission?
Bravelets was founded in 2012 and the Bravelets mission is to help people be brave during hard times. It is such a simple idea that started with one bracelet, in 10 colors, helping 10 different non-profits. We have now grown to over 30 products in 16 colors, helping close to 4,000 personal causes and nonprofits around the country. There are times in all of our lives where we need to be brave – whether for ourselves, for our family, for our friends, or even for a complete stranger. Bravelets bracelets are more than just something to wear on your wrist. All Bravelets jewelry and accessories are symbols of hope, strength and courage. They are designed to help you be brave in the toughest of times.
How did Bravelets begin?
Stephanie started Bravelets in 2012 after her mother was diagnosed with breast cancer. She wanted something the whole family could wear as a symbol of hope. Something they could look at every day, and remember to be brave. She also wanted something that gave back to the cause she cared about, which is why with every item purchased from Bravelets 10% is donated back to the cause of the customer’s choice.
How Bravelets has made an impact for nonprofits?
We offer the ability for anyone to set up a fundraiser for anything they feel they need to be brave for! Many people set up fundraisers in support of their favorite nonprofit, or they set up a personal fundraiser to raise money for their medical bills or local causes in their community. To date, we’ve raised over $2.6 million dollars for various personal causes and non-profits. Aside from the financial impact, the personal connection we’ve made with non-profits and hearing the stories of the people their research and mission’s effects is even more rewarding.
Bravelets gives nonprofits the opportunity to raise money in a special way
Why Bravelets chose to donate to nonprofits?
Bravelets is unique, because we provide a platform for anyone to choose to give back to any cause they wish to support. If they are searching for a specific cause but can’t seem to find the right one, we give them the opportunity to create a quick fundraising page for that cause!
Why did Bravelets choose to work with The Salgi Esophageal Cancer Research Foundation?
April is Esophageal Cancer Month, and we think it’s great to partner with non-profits that specifically work towards research and awareness about that cause! The Salgi Esophageal Cancer is making strides to bring awareness about early detection and we are proud to help support them.
What are Bravelets goals and plans for the future?
Bravelets is on track to raise another $2 Million for causes around the nation! We are excited about the support we are able give people each and every day, and the donations that are going back into our communities. We always have new products rolling out, and new causes joining our mission! We are excited to see how Bravelets continues to impact people’s lives and outlook on life!
Remember, through the end of April. 2017, you can donate 20% of your purchase to The Salgi Esophageal Cancer Research Foundation with code: SALGI20 at checkout. Visit our Bravelets Brave Page here. Please share this post with all of your family members and friends! Thank you!
The Salgi Esophageal Cancer Research Foundation has put together a video slideshow of the brave men and women who have been affected by esophageal cancer- those who have survived, those who have passed away and those who are currently fighting this horrific cancer.
Please considermaking a donation. This charity is sustained 100% by the generosity of our donors. In order to continue this mission of raising awareness, encouraging early detection and funding research of esophageal cancer, we ask you to consider making a tax-deductible donation. Click here to donate.
The goal of this video slideshow is to raise awareness of the fact that esophageal cancer is growing at a rapid rate and affecting people of all ages, race and gender. Please subscribe to our YouTube channel and share the video with your friends, family and social media. Be sure to tag us in your posts! (@SalgiFoundation) With your help, we will make a difference!
April is Esophageal Cancer Awareness Month. This year, The Salgi Esophageal Cancer Research Foundation is putting together a video slideshow of all the brave men and women who have been affected by esophageal cancer- those who have survived, those who have passed away and those who are currently fighting this horrific cancer
If you would like to submit a photo to be included in the slideshow, please email salgifoundation @ gmail.com by Friday, March 24, 2017 at 2PM EST. Please only send one photo per person to be included in the slideshow. Please also include the person’s name and if applicable, the birth year and year of passing. (I.e. John Smith, 1968-2014)
We ask you to consider making a donation to the charity along with your photo. While donations are not mandatory for inclusion in the slideshow, this charity is sustained 100% by the generosity of our donors. In order to continue this mission of raising awareness, encouraging early detection and funding research of esophageal cancer, we ask you to consider making a tax-deductible donation. Click here to donate.
The goal of this video slideshow is to raise awareness of the fact that esophageal cancer is growing at a rapid rate and affecting people of all ages, race and gender. With your help, we will make a difference!
“Cancer of the esophagus, the hollow tube connecting the oral cavity to the stomach, is usually treated surgically. Roswell Park Cancer Institute researchers have created a novel calculator that more readily identifies patients who may benefit from therapy that reduces the extent of the disease prior to surgery. The study has been published online ahead of print by the Journal of the American College of Surgeons.
Using the National Cancer Data Base, the Roswell Park team evaluated clinical data for 8,974 patients diagnosed with early-stage esophageal cancer. The database records information for as many as 70% of the nation’s cancer cases through participating hospitals. The researchers evaluated characteristics such as patients’ comorbidity score, tumor grade and neoadjuvant chemoradiation status (whether they had chemotherapy and/or radiation prior to surgery). Only preoperative data were used to develop the calculator. The scientists found that patients who benefit more from neoadjuvant chemoradiation included those whose tumors had metastasized to nearby lymph nodes, older patients and those with more aggressive cancers, such as tumors of higher grade and greater depth of invasion. These findings indicate that the calculator would assist physicians and patients with treatment decision-making.
“The use of calculators to estimate outcomes is becoming increasingly common, and is being applied to real-time clinical situations to aid in treatment decision-making and individualizing therapy,” says the lead author of the study, Emmanuel Gabriel, MD, PhD, of the Department of Surgical Oncology at Roswell Park.
“Our effort is a good example of how you can use large national databases to create calculators to guide and improve preoperative decision-making. Such tools can help us, for example, to avoid the toxic side effects of upfront chemoradiotherapy in a subset of patients. However, our calculator should be validated prospectively before firm conclusions can be drawn about its value in treatment selection,” notes the senior author of the study, Moshim Kukar, MD, Assistant Professor of Surgery in the Department of Surgical Oncology at Roswell Park.”
Emmanuel Gabriel, Kristopher Attwood, Rupen Shah, Steven Nurkin, Steven Hochwald, Moshim Kukar. Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma. Journal of the American College of Surgeons, 2017; DOI: 10.1016/j.jamcollsurg.2017.01.043
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
“Esophageal cancer patients who suffer loss of muscle mass (sarcopenia) during neoadjuvant therapy (chemotherapy prior to surgery) survive, on average, 32 months less than patients with no sarcopenia. This is the central finding of a recent study conducted at the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital. The study has recently been published in the European Journal of Cancer Surgery.
Esophageal cancer is the eighth most common type of cancer and sixth most common cause of death from cancer in Austria. According to “Statistik Austria,” approximately 420 people develop this type of cancer every year. This means that esophageal cancer is a rare form of cancer but the number of cases has grown rapidly over the past few years. The number of cases in men has risen sixfold and has quadrupled in women, men being more likely to develop this type of cancer than women.
Esophageal cancer is among the fastest and deadliest cancers in the United States and western world. In 2017, an estimated 16,940 will be diagnosed with esophageal cancer and there will be an estimated 15,690 deaths from esophageal cancer, in the United States.¹ Only 18.4% of patients diagnosed with esophageal cancer will survive 5(+) years.
Apart from smoking and high alcohol consumption, risk factors for esophageal cancer also include gastro-esophageal reflux disease and the resulting cell changes in the lower part of the oesophagus (Barrett metaplasia). The standard treatment for patients in which the tumour is advanced but not yet metastasised, is to give chemotherapy or a combination of chemotherapy and radiotherapy prior to surgery (multimodal therapy). In local carcinomas that are not advanced, surgery is the treatment of choice.
Nutrition and exercise affect chances of survival
In their study, experts in stomach and esophageal cancer from the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital (CCC GET-Unit, Head: Sebastian Schoppmann) investigated to what extent sarcopenia and body composition changed during multimodal therapy and whether this has any influence upon long-term survival. The results show that patients who suffered sarcopenia (loss of muscle mass below a defined threshold) at any time during treatment had a poorer prognosis for survival: on average, their period of survival was 32 months shorter than that of patients who were not diagnosed with sarcopenia. Sarcopenia was therefore identified as an independent risk factor.
Says Matthias Paireder, Department of Surgery (Head: Michael Gnant) of MedUni Vienna and Vienna General Hospital, member of the CCC-GET and lead author of the study: “Sarcopenia is not necessarily a side effect of chemotherapy. Many patients were already sarcopenic before the treatment and there was no significant progression of sarcopenia during treatment. The reasons for this loss of general muscle mass are poor nutrition and lack of exercise.”
New study planned
In a new study, the team headed up by Paireder and Schoppmann will investigate whether a programme that includes nutritional advice and physical training could significantly increase long-term survival for esophageal cancer patients.”
Medical University of Vienna. “Esophageal cancer: Loss of muscle mass represents a significant risk to survival.” ScienceDaily. ScienceDaily, 14 February 2017.
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Posted by salgiblogs 
The Salgi Esophageal Cancer Research Foundation 